Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

New developments in the pharmacologic treatment of obesity.

Fantasia HC.

Nurs Womens Health. 2013 Feb-Mar;17(1):53-62. doi: 10.1111/1751-486X.12006. Erratum in: Nurs Womens Health. 2013 Apr-May;17(2):84.

PMID:
23399013
2.

New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).

Shyh G, Cheng-Lai A.

Cardiol Rev. 2014 Jan-Feb;22(1):43-50. doi: 10.1097/CRD.0000000000000001. Review.

PMID:
24304809
3.

Two anti-obesity hopefuls and their safety.

Bello NT, Campbell SC.

Expert Opin Drug Saf. 2012 Sep;11(5):681-3. doi: 10.1517/14740338.2012.706277. Epub 2012 Jul 13. No abstract available.

PMID:
22788876
4.

The FDA's assessment of two drugs for chronic weight management.

Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C.

N Engl J Med. 2012 Oct 25;367(17):1577-9. doi: 10.1056/NEJMp1211277. Epub 2012 Oct 10. No abstract available.

5.

Nonincretin drugs in later-stage development.

Zimmerman MP, Mehr SR.

Am J Manag Care. 2014 Jan;20(1 Spec No.):E2. No abstract available.

6.

New medications for weight loss.

Murfin M.

JAAPA. 2012 Dec;25(12):59-60. No abstract available.

PMID:
23600006
7.

Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.

Kelly EM, Tungol AA, Wesolowicz LA.

J Manag Care Pharm. 2013 Oct;19(8):642-54. Review.

8.

ACS chemical neuroscience molecule spotlight on Qnexa.

Mercer SL.

ACS Chem Neurosci. 2011 Apr 20;2(4):183-4. doi: 10.1021/cn200023v.

9.

Two new drugs approved for obesity.

Johnson AM.

S D Med. 2012 Sep;65(9):356-7. No abstract available.

PMID:
23066610
10.

Obesity Epidemic: Pharmaceutical Weight Loss.

Curry SA.

R I Med J (2013). 2017 Mar 1;100(2):18-20.

PMID:
28246654
11.

2 new drugs for weight loss.

[No authors listed]

Med Lett Drugs Ther. 2012 Sep 3;54(1398):69-71. No abstract available. Erratum in: Med Lett Drugs Ther. 2012 Sep 17;54(1399):76.

PMID:
22992487
12.

A review of the metabolic effects of controlled-release Phentermine/Topiramate.

Kiortsis DN.

Hormones (Athens). 2013 Oct-Dec;12(4):507-16. Review.

13.

New pharmacological treatments for the management of obesity.

Hurt RT, Edakkanambeth Varayil J, Ebbert JO.

Curr Gastroenterol Rep. 2014;16(6):394. doi: 10.1007/s11894-014-0394-0. Review.

PMID:
24828101
14.

Recent advancements in drug treatment of obesity.

Carter R, Mouralidarane A, Ray S, Soeda J, Oben J.

Clin Med (Lond). 2012 Oct;12(5):456-60. Review.

PMID:
23101148
15.

Combination phentermine and topiramate extended release in the management of obesity.

Alfaris N, Minnick AM, Hopkins CM, Berkowitz RI, Wadden TA.

Expert Opin Pharmacother. 2015 Jun;16(8):1263-74. doi: 10.1517/14656566.2015.1041505. Review.

PMID:
25958964
16.

Unambiguous identification of obesity trials.

Zarin DA, Tse T.

N Engl J Med. 2013 Feb 7;368(6):580-1. doi: 10.1056/NEJMc1215018. No abstract available.

17.

Combination phentermine/topiramate for obesity treatment in primary care: a review.

Xiong GL, Gadde KM.

Postgrad Med. 2014 Mar;126(2):110-6. doi: 10.3810/pgm.2014.03.2746. Review.

PMID:
24685974
18.

Pharmacologic therapies for obesity.

Kaplan LM.

Gastroenterol Clin North Am. 2010 Mar;39(1):69-79. doi: 10.1016/j.gtc.2010.01.001. Review.

PMID:
20202580
19.

Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.

Bays H.

Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1777-801. doi: 10.1586/erc.10.125. Epub 2010 Aug 16. Review.

PMID:
20707765
20.

Overview of new antiobesity drugs.

Hainer V.

Expert Opin Pharmacother. 2014 Oct;15(14):1975-8. doi: 10.1517/14656566.2014.946904. Epub 2014 Aug 6. Review.

PMID:
25100293

Supplemental Content

Support Center